Letter: Tofacitinib, vedolizumab and ustekinumab in patients with ulcerative colitis-Authors' reply.
Saved in:
| Title: | Letter: Tofacitinib, vedolizumab and ustekinumab in patients with ulcerative colitis-Authors' reply. |
|---|---|
| Authors: | Desai A; Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida, USA., Regueiro M; Division of Gastroenterology & Hepatology, Cleveland Clinic Foundation, Cleveland, Ohio, USA., Kochhar GS; Division of Gastroenterology & Hepatology, Allegheny Health Network, Pittsburgh, Pennsylvania, USA. |
| Source: | Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2023 Dec; Vol. 58 (11-12), pp. 1243. |
| Publication Type: | Letter; Comment |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 8707234 Publication Model: Print Cited Medium: Internet ISSN: 1365-2036 (Electronic) Linking ISSN: 02692813 NLM ISO Abbreviation: Aliment Pharmacol Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1365-2036 |
|---|---|
| DOI: | 10.1111/apt.17750 |
